Application of micro-fluidic chip in capture and detection of heterogeneous CTCs in colon cancer

By combining microfluidic chips with helical separation and immune capture technologies, the problems of low efficiency and high false negative rate in CTC capture and detection have been solved. This has enabled efficient separation and sensitive detection of heterogeneous CTCs, providing a basis for non-invasive assessment and treatment adjustment for cancer patients.

CN118962129APending Publication Date: 2024-11-15XUZHOU MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411120989.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing technologies struggle to efficiently capture and detect circulating tumor cells (CTCs), especially given the rarity and heterogeneity of CTCs, resulting in low detection efficiency and high false negative rates, which negatively impact cancer treatment outcomes.

Method used

Using microfluidic chips combined with helical separation and immune capture technologies, CTCs were separated, captured, and detected by cascaded helical separation chips and immune capture detection chips, using Gel-GO hydrogel modified with NH2-EpCAM and NH2-Vimentin aptamers and mesoporous platinum nanoparticle probes (mPtNPs/Apt).

Benefits of technology

It achieves efficient separation and sensitive detection of heterogeneous CTCs, maintains cell viability, improves capture efficiency and detection specificity, and provides a non-invasive tool for assessing the hematogenous metastatic status of cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962129A_ABST
    Figure CN118962129A_ABST
Patent Text Reader

Abstract

The invention discloses application of a micro-fluidic chip in capture and detection of heterogeneous CTCs in colon cancer, and the spiral sorting micro-fluidic chip prepared by the invention can rapidly enrich the heterogeneous CTCs and capture epithelial expression type and interstitial expression type CTCs cells in batches on an immunocapture detection chip; meanwhile, the mPtNPs probe modified by two different aptamers is used for rapidly detecting the aptamer. Compared with the traditional CTCs research method, the method provided by the invention can make sensitive and specific response to heterogeneous CTCs while maintaining high capture efficiency, and the captured CTCs still have high activity. By means of a chip technology, the research of CTCs capture, detection and identification integration is further realized. The invention provides a powerful tool for developing clinical application of the CTCs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cell detection devices, and in particular to an application of a microfluidic chip in the capture and detection of heterogeneous CTCs in colon cancer. Background Art

[0002] There are millions of new cases of colon cancer and hundreds of thousands of deaths worldwide each year. The main cause of treatment failure and death in patients with colon cancer is tumor metastasis. Among them, cancer cells that fall off from the primary site and enter the blood circulation are called circulating tumor cells (CTCs). The number of CTCs can reflect tumor burden and detection efficacy, and is earlier than standard imaging changes, so it is considered to be an alternative predictor of early diagnosis, chemotherapy efficacy evaluation and cancer prognosis. However, the detection and analysis of CTCs face two major challenges: rarity and phenotypic heterogeneity. In human cancer cell lines and mouse models, epithelial CTCs are transformed into mesenchymal CTCs after undergoing EMT (epithelial-mesenchymal transition), and mesenchymal CTCs are more invasive. The number of CTCs and EMT typing in the peripheral blood of patients with various cancers are closely related to prognosis. The rarity of CTCs means that there are hundreds of millions of blood cells in 1 mL of blood, while the number of CTCs is only tens to hundreds, which greatly interferes with the detection of CTCs by white blood cells. The heterogeneity of CTCs means that during the EMT process of CTCs, the epithelial characteristics gradually disappear, and the expression of EpCAM (epithelial cell adhesion molecule) on the surface of tumor cells decreases or even disappears completely, resulting in reduced efficiency in the identification and capture of CTCs. Therefore, efficient and sensitive CTCs enrichment and detection technology is the basis for the clinical application of CTCs. Detection of peripheral blood CTCs and EMT molecular typing can help to non-invasively evaluate the hematogenous metastasis status of cancer patients, adjust treatment plans as early as possible, and improve their prognosis.

[0003] In recent years, a variety of methods and strategies for the efficient enrichment of CTCs have been developed, mainly including physical separation and immunoaffinity methods that utilize the biophysical properties of CTCs themselves. Generally, the efficiency and purity of physical separation methods are low, and they can cause mechanical damage to the captured CTCs, thereby affecting cell viability. The immunoaffinity method is mainly an enrichment technology based on the immunoaffinity characteristics between antibodies or aptamers and antigens highly expressed on the surface of CTCs (currently mainly epithelial cell adhesion factor (EpCAM) and cytokeratin), but this technology also has some defects, such as the heterogeneity of CTCs antigen expression, which makes CTCs easy to lose during capture, resulting in false negative detection. Therefore, combining physical separation and immunoaffinity methods can complement each other's advantages, while further improving the enrichment efficiency and purity of CTCs, while maintaining high cell viability to the greatest extent.

[0004] Microfluidics is a technology used to control small-scale fluid devices and systems. It can integrate biological and chemical experiments of trace samples on a chip to achieve microfluidic manipulation. Compared with traditional analytical devices, this technology can shorten experimental time, reduce contamination risks, improve automation efficiency, and have higher sensitivity and reliability. Summary of the invention

[0005] Purpose of the invention: The present invention provides an application of a microfluidic chip in the capture and detection of heterogeneous CTCs in colon cancer. The microfluidic chip provided by the present invention can detect peripheral blood CTC and EMT molecular typing, which is helpful for non-invasive assessment of the hematogenous metastasis status of cancer patients, and provides an effective solution for early diagnosis and adjustment of treatment plans for patients with colon cancer.

[0006] Technical solution: Application of a microfluidic chip in the capture and detection of heterogeneous CTCs in colon cancer, comprising the following steps:

[0007] Step 1: preparing a microfluidic chip;

[0008] The microfluidic chip comprises a spiral separation chip and an immune capture detection chip arranged in cascade; the spiral separation chip comprises a single spiral microfluidic channel, the first end of the single spiral microfluidic channel is located inside the single spiral microfluidic channel, the second end of the single spiral microfluidic channel is located outside the single spiral microfluidic channel, the first end of the single spiral microfluidic channel is provided with two inlets, namely a sheath inlet and a sample inlet, and the sheath inlet is located on the inside, and the sample inlet is located on the outside; the second end of the single spiral microfluidic channel is provided with two outlets, namely a target outlet and a waste liquid outlet, and the target outlet is located on the inside, and the sample outlet is located on the outside. The target outlet is located on the inner side, and the waste liquid outlet is located on the outer side; the immune capture detection chip is provided with an import channel, a first groove, a connecting channel, a second groove, and an export channel which are connected in sequence; the first groove is an epithelial CTCs capture detection area, and the second groove is an interstitial CTCs capture detection area; the first groove is provided with a Gel-GO hydrogel modified with an NH2-EpCAM aptamer, and the second groove is provided with a Gel-GO hydrogel modified with an NH2-Vimentin aptamer; the target outlet of the spiral separation chip is connected with the import channel of the immune capture detection chip;

[0009] Step 2: Isolation of heterogeneous CTCs;

[0010] The blood sample to be tested first enters the spiral separation chip, and then is separated to obtain heterogeneous CTCs; the heterogeneous CTCs include epithelial CTCs and mesenchymal CTCs;

[0011] Step 3: Capture of heterogeneous CTCs;

[0012] The heterogeneous CTCs flowing out of the target outlet of the spiral separation chip enter the immune capture detection chip through the inlet channel of the immune capture detection chip, and the epithelial CTCs in the blood sample to be detected are captured by the first groove, and the interstitial CTCs are captured by the second groove;

[0013] Step 4: Detection of heterogeneous CTCs;

[0014] 1) Drop the SH2-EpCAM aptamer-modified mPtNPs solution into the first groove, i.e., mPtNPs / Apt EpCAM solution, and then add a mixed solution of TMB and H2O2 after incubation;

[0015] 2) Add the solution of mPtNPs modified with SH-Vimentin aptamer into the second groove, i.e., mPtNPs / Apt vimentin solution, and then add a mixed solution of TMB and H2O2 after incubation;

[0016] 3) The mPtNPs were used to catalyze the color development reaction of TMB, and the relationship between the absorbance value and the number of cells after the reaction between the epithelial CTCs capture detection area and the mesenchymal CTCs capture detection area was detected, and the number of epithelial CTCs and mesenchymal CTCs was calculated.

[0017] Furthermore, in step one:

[0018] 1) The channel width of the single spiral microfluidic channel is 350 μm, the depth is 150 μm, and the curvature diameter is 1 cm;

[0019] 2) In the immune capture detection chip, the width and depth of the inlet channel, the connecting channel, and the outlet channel are all 1 mm, the depth of the first groove and the second groove is 6 mm, and the bottom area is 0.95 cm 2 .

[0020] 3. The use according to claim 1, characterized in that in step 1, the preparation method of the Gel-GO hydrogel modified with NH2-EpCAM aptamer and the Gel-GO hydrogel modified with NH2-Vimentin aptamer on the immune capture detection chip is as follows:

[0021] Step 1.1), preparing gelatin-graphene oxide hydrogel;

[0022] 1 mL of 2 mg / mL graphene oxide suspension was taken into a centrifuge tube and dispersed evenly by ultrasound; then 15 wt% gelatin solution was added to 5 mL and stirred at 37°C for 30 min to obtain gelatin-graphene oxide hydrogel, i.e., Gel-GO hydrogel; the concentration of graphene oxide in Gel-GO hydrogel was 0.4 mg / mL;

[0023] Step 1.2) Adaptogenized Gel-GO hydrogel;

[0024] The prepared Gel-GO hydrogel was added into the first groove and the second groove, and placed in a 4°C refrigerator for 30 minutes to gradually change the Gel-GO hydrogel from a solution state to a solid state; then a mixed solution of 4 mg / mL EDC and 6 mg / mL NHS was added, and the mixture was reacted at room temperature for 2 hours to activate the carboxyl group. After the activation was completed, the mixture was rinsed with a PBS buffer solution;

[0025] Add 200 μL of 1.0 μM NH2-EpCAM aptamer to each of the first grooves, place in a 4°C refrigerator, and incubate for 12 h. After the incubation, rinse with PBS buffer solution to obtain NH2-EpCAM aptamer-modified Gel-GO hydrogel;

[0026] Add 200 μL of 1.0 μM NH2-Vimentin aptamer into the second groove, place it in a 4°C refrigerator, and incubate it at low temperature for 12 hours; after incubation, rinse it with PBS buffer solution to obtain NH2-Vimentin aptamer-modified Gel-GO hydrogel.

[0027] Furthermore, in step 2, the optimal separation flow rate for the blood sample to be tested to enter the spiral separation chip is a sample flow rate of 350 μL / min and a sheath flow rate of 700 μL / min.

[0028] Furthermore, in step 4, mPtNPs / Apt EpCAM Solution and mPtNPs / Apt vimentin The solution was prepared as follows:

[0029] 1) Mix 100.0 μL of 15.0 μM SH-EpCAM aptamer and SH-Vimentin aptamer with 2.5 μL of 1.0 M TCEP solution respectively and incubate at room temperature for 30 min to activate the thiol groups;

[0030] 2) After activation, 1.0 mL and 5 mg / mL of mPtNPs were vortexed and mixed with the activated SH-EpCAM aptamer and SH2-Vimentin aptamer respectively to make the final concentration of the aptamer 1.0 μM;

[0031] 3) Finally, the mixed solution was reacted in a vertical suspension instrument at room temperature for 12 h to obtain two types of mPtNPs modified with SH-EpCAM aptamer and SH-Vimentin aptamer, which were respectively denoted as mPtNPs / Apt EpCAM and mPtNPs / Apt vimentin ;

[0032] 4) After the reaction, centrifuge at 12,000 rpm for 15 min to remove the unbound aptamers in the supernatant, and finally redisperse in PBS solution to obtain mPtNPs / Apt EpCAM Solution and mPtNPs / Apt vimentin Solution, store at 4°C.

[0033] Furthermore, step four is specifically as follows:

[0034] 1) Add mPtNPs / Apt into the first groove EpCAM The volume of the solution was 100 μL, mPtNPs / Apt EpCAM The concentration of mPtNPs / Apt was 20 μg / mL. After incubation at room temperature for 30 min, the excess mPtNPs / Apt EpCAM The solution was washed off, and 200 μL of a mixed solution of 0.5 mM TMB and 50 mM H2O2 was added. After incubation for 10 min, TMB reaction stop solution without sulfuric acid was added;

[0035] 2) Add mPtNPs / Apt into the second groove vimentin 100 μL of solution, mPtNPs / Apt vimentin The concentration was 20 μg / mL. After incubation at room temperature for 30 min, the excess mPtNPs / Apt was washed off and 200 μL of a mixed solution of 0.5 mM TMB and 50 mM H2O2 was added. After incubation for 10 min, TMB reaction termination solution without sulfuric acid was added.

[0036] 3) Epithelial CTCs capture detection area, the relationship between the absorbance value after reaction and the number of epithelial CTCs cells is as follows:

[0037] Y=0.403lgX-0.063,R 2 =0.994;

[0038] Among them, X represents absorbance and Y represents the number of cells;

[0039] 4) In the interstitial CTCs capture detection area, the relationship between the absorbance value after the reaction and the number of interstitial CTCs cells is as follows:

[0040] Y=0.345lgX-0.014,R 2 =0.994;

[0041] Among them, X represents absorbance and Y represents the number of cells.

[0042] Beneficial effects: The present invention discloses an application of a microfluidic chip in the capture and detection of heterogeneous CTCs in colon cancer. The spiral sorting microfluidic chip prepared by the present invention rapidly enriches heterogeneous CTCs, and captures epithelial expression type and mesenchymal expression type CTCs cells in batches on the immune capture detection chip, and simultaneously uses two mPtNPs probes modified with different aptamers to rapidly detect them. Compared with traditional CTCs research methods, the present invention can respond sensitively and specifically to heterogeneous CTCs while maintaining a high capture efficiency, and the captured CTCs are still highly active. With the help of chip technology, the integrated research on CTCs capture, detection and identification is further realized. The present invention provides a powerful tool for exploring the clinical application of CTCs. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 Schematic diagram of the structure of the microfluidic chip prepared by the present invention, A is a schematic diagram of the structure of the spiral separation chip, and B is a schematic diagram of the structure of the immune capture detection chip.

[0044] Figure 2 Characterization of mesoporous platinum nanoparticles (mPtNPs).

[0045] Figure 3 X-ray diffraction (XRD) spectrum and electron diffraction (SAED) pattern of mesoporous platinum nanoparticles (mPtNPs).

[0046] Figure 4 SEM characterization of Gel-GO hydrogel. Figure 5 This is the infrared spectrum of Gel-GO hydrogel.

[0047] Figure 6 Immunofluorescence images of EpCAM expression levels in E-SW480 cells before and after TGF-β treatment.

[0048] Figure 7 This is an immunofluorescence image of Vimentin expression levels in E-SW480 cells before and after TGF-β treatment.

[0049] Figure 8 The SEM images of E-SW480 and M-SW480 cells captured by Gel-GO / Apt hydrogel in PBS, where A corresponds to E-SW480 and B corresponds to M-SW480 cells.

[0050] Fig. 9This is a comparison chart of the CTCs capture performance of different materials, where A is Gel, B is Gel / Apt, C is Gel-GO, D is the inverted fluorescence image of Gel-GO / Apt capturing E-SW480, and E is the capture effect of different materials on E-SW480.

[0051] Fig.10 is the capture efficiency of CTCs in two media, PBS and mixed cell solution containing THP-1; A is the capture efficiency of Gel-GO / Apt hydrogel for E-SW480 cells with different concentrations, A is the capture efficiency of Gel-GO / Apt hydrogel for M-SW480 cells with different concentrations; C is the linear working curve of E-SW480 cells; D is the linear working curve of M-SW480 cells.

[0052] Fig.11 is the absorbance of TMB, TMB+H2O2, and TMB+H2O2 and CTCs specifically bound to mPtNPs / Apt.

[0053] Fig.12 These are SEM images at different magnifications after specific binding of mPtNPs / Apt to CTCs. The scale bar in A is 2 μm, and the scale bar in B is 1 μm.

[0054] Fig.13 The absorbance in different detection zones was obtained after E-SW480, A549, MCF-7, M-A549, Hela and THP-1 cells were captured by chip sorting and then incubated with mPtNPs / Apt.

[0055] Fig.14 It is a linear relationship diagram between the number of CTCs and the absorbance intensity of TMB; A is the absorption spectrum of different numbers of E-SW480 cells in PBS after incubation with mPtNPs / Apt probe; B is the absorption spectrum of different numbers of M-SW480 cells in PBS after incubation with mPtNPs / Apt probe; C is the linear relationship curve between the number of E-SW480 and M-SW480 cells and TMB absorbance in PBS.

[0056] Fig.15 : is the linear regression curve between different numbers of cells in PBS and mixed cell solution and TMB absorbance values; wherein, A is the linear regression curve between different numbers of E-SW480 and TMB absorbance values; B is the linear regression curve between M-SW480 cells and TMB absorbance values.

[0057] Fig.16The results of detecting the number of heterogeneous CTCs in the blood of 20 patients with colon cancer and 10 healthy people using microfluidic chip combined with mPtNPs / Apt probe.

[0058] Fig.17 The relationship between the total number of CTCs and the clinical stage of the patient and the ratio of epithelial and stromal CTCs to the total number of CTCs in different clinical stages. Among them, A is the relationship between the total number of CTCs and the clinical stage of the patient; B is the ratio of epithelial and stromal CTCs to the total number of CTCs in different clinical stages. DETAILED DESCRIPTION

[0059] The technical solution of the present invention is described in detail below with reference to the accompanying drawings, but the protection scope of the present invention is not limited to the embodiments. The reagents involved in the embodiments can be purchased or configured.

[0060] Example 1: Preparation of microfluidic chip

[0061] (I) The microfluidic chip prepared in this embodiment is a cascade chip, such as Figure 1 As shown, it includes a spiral separation chip and an immune capture and detection chip arranged in series, and the target outlet of the spiral separation chip is connected to the inlet channel of the immune capture detection chip.

[0062] Spiral separation chip: The spiral separation chip adopts the principle of inertial separation, and utilizes the difference in inertial lift and Dean resistance of particles of different sizes in the spiral channel, so as to focus at different positions, and achieve the purpose of collecting target cells by reasonably setting the outlet. The length and width of the spiral separation chip are 2.5cm×2.8cm. In order to meet the requirements of collecting target cells from diluted blood, the channel width of the spiral separation chip designed in this embodiment is 350μm, the depth is 150μm, and the curvature diameter is 1cm.

[0063] The spiral separation chip includes a single spiral microfluidic channel, the first end of the single spiral microfluidic channel is located inside the single spiral microfluidic channel, the second end of the single spiral microfluidic channel is located outside the single spiral microfluidic channel, the first end of the single spiral microfluidic channel is provided with two inlets, namely a sheath flow inlet 1 and a sample inlet 2, and the sheath flow inlet 1 is located on the inner side and the sample inlet 2 is located on the outer side; the second end of the single spiral microfluidic channel is provided with two outlets, namely a target outlet 3 and a waste liquid outlet 4, and the target outlet is located on the inner side and the waste liquid outlet is located on the outer side.

[0064] The sheath inlet 1 and the sample inlet 2 are both arranged inside the single spiral microfluidic channel, and the target outlet 3 and the waste liquid outlet 4 are both outside, so as to be connected with the immune capture detection chip. During the separation process, the sample and the sheath liquid enter the single spiral microfluidic channel from different inlets under the action of the syringe pump, and under the action of inertial lift and Dean drag, CTCs, white blood cells and red blood cells of different sizes are separated at different positions, and the larger CTCs are separated on the inner side of the channel and collected by the target outlet, and flow into the subsequent immune capture detection chip, while the relatively smaller white blood cells and red blood cells (PBS washing solution, etc.) are separated on the outer side of the channel and collected by the waste liquid outlet.

[0065] Immunocapture detection chip: The immune capture detection chip is provided with an import channel 5, a first groove 6, a connecting channel 7, a second groove 8, and an export channel 9 which are connected in sequence; the first groove 6 is an epithelial CTCs (epithelial circulating tumor cells) capture detection area, and the second groove 8 is an interstitial CTCs (interstitial circulating tumor cells) capture detection area; the first groove 6 is provided with a Gel-GO hydrogel modified with an NH2-EpCAM aptamer, and the second groove 8 is a Gel-GO hydrogel modified with an NH2-Vimentin aptamer. The length and width of the immune capture detection chip are 3.0cm×3.5cm. The channel width and depth are both 1mm, the depth of the two grooves is 6mm, and the bottom area of ​​the two grooves is 0.95cm 2 After the target cells enter the immune capture chip, the channel becomes wider and the flow rate slows down, which prolongs the contact time between CTCs and Gel-GO / Apt hydrogel, thus improving the capture efficiency of CTCs.

[0066] Working principle of microfluidic chip: 1) Separation of heterogeneous CTCs: The blood sample to be tested first enters the spiral separation chip, and then separates heterogeneous CTCs; the heterogeneous CTCs include epithelial CTCs and interstitial CTCs; 2) Capture of heterogeneous CTCs: The heterogeneous CTCs flowing out of the target outlet of the spiral separation chip enter the immune capture detection chip through the inlet channel of the immune capture detection chip, and the epithelial CTCs in the blood sample to be tested are captured by the first groove, and the interstitial CTCs are captured by the second groove; thus, the partitioned capture of heterogeneous CTCs is achieved. 3) Detection of heterogeneous CTCs: After the capture is completed, mPtNPs modified with SH2-EpCAM (epithelial cell adhesion molecule) aptamers, TMB (3,3',5,5'-tetramethylbenzidine), and H2O2 are added to the first groove; mPtNPs modified with SH2-Vimentin (vimentin) aptamers, TMB, and H2O2 are added to the second groove. The mPtNPs were used to catalyze the color development reaction of TMB. The relationship between the absorbance value after the reaction and the number of cells was used to calculate the number of epithelial CTCs and mesenchymal CTCs, thereby achieving zoning detection of CTCs captured in different regions.

[0067] Microfluidic chip use effect and air tightness verification: The diluted blood sample (1ml blood from healthy volunteers) was injected into the microfluidic chip through a syringe pump. The result: the target cells collected at the target port were almost transparent, which preliminarily showed that most of the red blood cells were separated in the separation chip. The Gel-GO hydrogel prepared in this embodiment is brown, and the Gel-GO / Apt hydrogel in the capture area shows light brown when not in use, which indicates that the Gel-GO / Apt hydrogel has been successfully modified into the chip. After the CTCs in the blood sample were separated and captured by the chip, mPtNPs / Apt, TMB, and H2O2 were added. Due to the activity of the mPtNPs nanozyme, mPtNPs / Apt catalyzed TMB, which can convert colorless TMB into blue oxidized TMB (TMBox), so the capture area showed a light blue color, which indicates that the color reaction successfully occurred. In the above experiment, no extravasation occurred in the blood sample, indicating that the chip has good air tightness.

[0068] (II) Preparation of Gel-GO / Apt hydrogel and mPtNPs / Apt

[0069] 1. Solution preparation;

[0070] 1) Preparation of 1.0 μM NH2-EpCAM aptamer and NH2-Vimentin aptamer solutions: The powder dispersed on the wall of the Ep tube containing the aptamer was collected by centrifugation at 6000 rpm for 1 min, and then a specified volume of PBS solution (pH=7.4) that can be prepared to an aptamer concentration of 10.0 μM was added to the Ep tube. After vortex mixing, PBS solution was added to the aptamer solution to dilute it to 1.0 μM.

[0071] 2) Preparation of 15.0 μM SH-EpCAM aptamer and SH-Vimentin aptamer solutions: The powders dispersed on the wall of the Ep tube containing the aptamer were collected by centrifugation at 6000 rpm for 1 min, and then a specified volume of PBS solution (pH = 7.4) was added to the Ep tubes, and vortexed thoroughly to prepare 15.0 μM aptamer solutions.

[0072] 3) Preparation of 1.0 μM NH2-EpCAM-FAM aptamer and NH2-Vimentin-Ned aptamer solutions: In the dark, the powder dispersed on the wall of the Ep tube containing the aptamer was collected by centrifugation at 6000 rpm for 1 min, and a specified volume of PBS solution (pH=7.4) that can be prepared to an aptamer concentration of 10.0 μM was added to the Ep tube. After vortex mixing, PBS solution was added to the aptamer solution to dilute it to 1.0 μM.

[0073] 4) Preparation of mesoporous platinum nanoparticles (mPtNPs): 150 mg of KBr and 30 mg of Pluronic F-127 (pore directing agent) were added to 2 mL of deionized water and dissolved by ultrasound. Then, 0.75 mL of 40 mM H2PtCl6 solution was added, followed by gentle shaking in ultrasound until the color of the solution changed from yellow to orange. Finally, 2 mL of ascorbic acid solution (100 mM, obtained by mixing 35.224 mg and 2 mL of deionized water) was added. The solution was incubated in an oil bath at 70°C for 12 h, and the resulting sample was collected by centrifugation at 12,000 rpm for 20 min, and then washed with anhydrous ethanol and deionized water for 4 consecutive cycles. Finally, the pure mPtNPs were resuspended in 4 mL of water.

[0074] 2. Preparation of aptamer-modified mesoporous platinum nanoparticles (mPtNPs / Apt);

[0075] 1) 100.0 μL of 15.0 μM SH-EpCAM aptamer and SH-Vimentin aptamer were mixed with 2.5 μL of 1.0 M TCEP solution respectively, and incubated at room temperature for 30 min to activate the thiol groups. TCEP refers to tris(2-carboxyethyl)phosphine hydrochloride.

[0076] 2) After activation, 1.0 mL and 5 mg / mL of mPtNPs were vortexed and mixed with the activated SH-EpCAM aptamer and SH-Vimentin aptamer, respectively, to make the final concentration of the aptamer 1.0 μM;

[0077] 3) Finally, the mixed solution was reacted in a vertical suspension incubator at room temperature for 12 hours to obtain two types of mPtNPs modified with SH-EpCAM aptamer and SH-Vimentin aptamer.

[0078] 4) After the reaction, centrifuge at 12,000 rpm for 15 min to remove unbound aptamers in the supernatant, and finally redisperse in 1.0 mL PBS (pH=7.4) solution and store at 4°C for future use.

[0079] 3. Preparation of Gel-GO / Apt hydrogel;

[0080] 1) Preparation of gelatin-graphene oxide hydrogel (Gel-GO):

[0081] 1 mL of 2 mg / mL graphene oxide suspension was drawn into an Eppendorf tube and dispersed evenly by ultrasound. Then 15 wt% gelatin solution (1 g of gelatin powder was slowly added to 5.67 mL of heated deionized water under stirring conditions and dispersed evenly) was added to 5 mL and stirred at 37°C for 30 min to obtain graphene oxide-gelatin hydrogel (Gel-GO), with a graphene oxide concentration of 0.4 mg / mL.

[0082] 2) Preparation of aptamerized Gel-GO hydrogel (Gel-GO / Apt):

[0083] The prepared Gel-GO hydrogel was added to the capture area (first groove and second groove) of the capture chip, and then placed in a 4°C refrigerator for 30 minutes to gradually change the Gel-GO hydrogel from a solution state to a solid state. Then, a 4mg / mL EDC and 6mg / mL NHS mixed solution was added (40mg of EDC and 60mg of NHS were added to 5mL of deionized water, mixed, and the same volume of EDC / NHS solution was mixed), and the reaction was carried out at room temperature for 2h to activate the carboxyl group. After activation, the area was repeatedly rinsed with PBS buffer solution (pH = 7.4), and then 200μL NH2-EpCAM aptamer (1.0μM) was added to the first groove;

[0084] 200 μL NH2-Vimentin aptamer (1.0 μM) was added to the second groove and placed in a 4°C refrigerator for incubation at low temperature for 12 h. After incubation, it was rinsed three times with PBS buffer solution (pH = 7.4) to obtain the aptamerized Gel-GO hydrogel (Gel-GO / Apt) for the capture of heterogeneous CTCs.

[0085] 4. Characterization of prepared mPtNPs and Gel-GO / Apt hydrogel;

[0086] 1) Characterization of mesoporous platinum nanoparticles (mPtNPs):

[0087] The prepared mesoporous platinum nanoparticles were characterized by scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Figure 2 As shown in the figure, A and B are SEM (scanning electron microscope) images of mPtNPs, with scales of 500nm and 400nm respectively; C and D are TEM (transmission electron microscope) images of mPtNPs, with scales of 0.2μm and 20nm respectively; E is a high-resolution TEM image of mPtNPs, with a scale of 10nm; F is the particle size distribution curve of mPtNPs. As shown in A and B, the size of mPtNPs is uniform and evenly distributed, with a regular spherical structure; C and D show the mesoporous structure of mPtNPs; the lattice fringes of Pt particles can be seen in E, with a lattice spacing of 0.23nm, corresponding to the fcc Pt (111) plane; according to the particle size statistics of F, the average particle size of mPtNPs is about 112.3nm. Figure 2 In Figure 1, A is the XRD pattern of mPtNPs, and B is the SAED diffraction pattern of mPtNPs. In Figure 1, four characteristic diffraction peaks of Pt particles appear at the positions of (111), (200), (220), and (311) planes, indicating a face-centered cubic (fcc) structure. Figure 3 The selected area electron diffraction (SAED) pattern in Figure B shows obvious diffraction rings, which indicates that the mPtNPs have a polycrystalline structure, and the four diffraction rings correspond to the (111), (200), (220) and (311) planes of MPN. These results show that the mPtNPs prepared in this example are highly uniformly synthesized and well dispersed, and have a mesoporous structure.

[0088] 2) Characterization of Gel-GO / Apt hydrogel;

[0089] 2.1) SEM characterization of Gel-GO hydrogel:

[0090] like Figure 4 As shown, Figure 4A and B are SEM images of Gel and Gel-GO hydrogels, respectively. Compared with the relatively smooth surface of gelatin, the surface of Gel-GO hydrogel becomes rough and has a micron-level wrinkled structure. The presence of these wrinkles increases the contact area between the hydrogel and the cells, which is conducive to enhancing the recognition of tumor cells and thus improving the capture efficiency. Figure 4 C in the figure is the XRD diagram of graphene oxide and freeze-dried Gel-GO hydrogel. It can be seen that the diffraction peak of graphene oxide appears at 10.6°, and the corresponding interlayer spacing is 0.83nm. Compared with graphene oxide, no obvious diffraction peak of graphene oxide is observed in the freeze-dried hydrogel, which indicates that graphene oxide has been evenly dispersed in the network structure of the hydrogel, or the degree of re-aggregation of graphene oxide is low during the formation of the hydrogel. Figure 4 D in the figure is a diagram showing the transition between the sol state (liquid state) of Gel-GO hydrogel at 37°C and the gel state (solid state) at 25°C. At 25°C (room temperature), Gel-GO hydrogel is a solid gel, providing a platform for capturing cells. After the CTCs capture and detection is completed, the Gel-GO hydrogel in the chip is removed by heating or passing warm water (37°C), thereby achieving the reuse of the chip.

[0091] 2.2) Infrared spectroscopy analysis of Gel-GO hydrogel;

[0092] like Figure 5 As shown, the blue curve is the spectrum of GO, the red curve is the spectrum of gelatin, and the black curve is the spectrum of GO and Gel composite. Figure 5 It can be seen that there is a strong physical binding effect between the two components in the Gel-GO hydrogel.

[0093] 2.3) Inverted fluorescence microscopy and fluorescence spectrophotometer characterization of Gel-GO / Apt hydrogel;

[0094] The fluorescent labeling method was used to verify the successful linking of NH2-EpCAM aptamers and NH2-Vimentin aptamers to Gel-GO hydrogel. First, the other end of the NH2-EpCAM aptamer was modified with a FAM fluorescent group, and the other end of the NH2-Vimentin aptamer was modified with a Ned fluorescent group. The two aptamers labeled with different fluorescent groups were co-incubated with the Gel-GO hydrogel, and the Gel-GO hydrogel modified with aptamers not labeled with fluorescent groups was used as the control group. Then, the image was observed and photographed under an inverted fluorescence microscope. Under the fluorescent field of view, the Gel-GO hydrogel modified with the aptamer labeled with the FAM fluorescent group and the hydrogel modified with the aptamer labeled with the Ned fluorescent group showed green fluorescence and red fluorescence, while the control group modified with the aptamer not labeled with fluorescein did not show any fluorescent signal. This result shows that NH2-EpCAM aptamers and NH2-Vimentin aptamers have been successfully linked to the Gel-GO hydrogel.

[0095] Example 2: Optimization of capture and detection conditions of CTCs using microfluidic chips

[0096] (i) Preparation of solution: the prepared solution should be stored in a refrigerator at 4°C;

[0097] 1) Preparation of 1% Triton-X 100 solution: Add 1.0 mL Triton-X 100 to a beaker, add an appropriate amount of PBS solution with a pH of 7.4, and transfer to a 100.00 mL volumetric flask to make up to volume.

[0098] 2) Preparation of 1% BSA solution: weigh 2.0 g of BSA powder and add it into a beaker. Add deionized water and transfer to a 100.00 mL volumetric flask to make up the volume after dissolving.

[0099] 3) Preparation of 0.10M HAc-NaAc buffer solution (pH=5.5): weigh 4.674g sodium acetate and absorb 570μL acetic acid, add appropriate amount of deionized water, dissolve and transfer to a 100.00mL volumetric flask to make up to volume.

[0100] 4) Preparation of 100 mM H2O2 solution: Add 1.0 mL of 30% H2O2 solution to 10 mL of 0.1 M HAc-NaAC buffer (pH=5.5), then gradually dilute to 100 mM and store at 4°C.

[0101] 5) Preparation of 1 mM TMB solution: Weigh 31.327 mg of TMB hydrochloride and dissolve it in 10 mL of 0.1 M HAc-NaAC buffer (pH=5.5). After dissolution, continue to dilute 10 times.

[0102] 6) Preparation of a mixed solution of 0.5 mM TMB and 50 mM H2O2: Pipette an appropriate amount of 1 mM TMB solution and add the same volume of 100 mM H2O2 solution and mix well.

[0103] (ii) Optimization of flow rate in the separation chip;

[0104] Polystyrene microspheres with particle sizes of 5μm, 10μm, and 20μm were selected to simulate red blood cells, white blood cells, and CTCs. Microspheres of different particle sizes were collected at the target port, the volume was calculated by weighing, and then the density was measured by using the particle mode of the cell counter to calculate the number of microspheres of each particle size in the sample. 1) The sheath flow rate was fixed at 800μL / min, and the flow rate of the sample injection port was changed, and then microspheres of different particle sizes were collected at the target port, and the separation efficiency of microspheres of each particle size was calculated. The optimal injection port flow rate was determined by the flow rate with the largest number of polystyrene microspheres of 20μm and the smallest number of microspheres of 5μm and 10μm. 2) The sample injection flow rate was fixed at 350μL / min, and the flow rate of the sheath flow was changed, and then microspheres of different particle sizes were collected at the target port, and the separation efficiency of microspheres of each particle size was calculated. The optimal sheath flow rate was determined by the flow rate at which the number of polystyrene microspheres with a particle size of 20 μm was the largest and the number of microspheres with a particle size of 5 μm and 10 μm was the smallest.

[0105] The optimal separation flow rate of the chip was finally obtained as 350 μL / min sample flow rate and 700 μL / min sheath flow rate. At this flow rate, the separation efficiency of CTCs was 100%, the separation efficiency of leukocytes was 75.13%, and the separation efficiency of erythrocytes was 94.86%, indicating that most of the leukocytes and erythrocytes can be removed by this separation chip, thereby obtaining high-purity CTCs.

[0106] (iii) Cell culture and treatment methods;

[0107] The CTCs-positive cells were set as the experimental group, and the CTCs-negative cells were set as the control group. The positive group included E-SW480 cells (epithelial colon cancer cells), M-SW480 cells (stromal colon cancer cells), A549 (human lung adenocarcinoma cells), MCF-7 (human breast cancer cells), and Hela (human cervical cancer cells); the negative group was THP-1 cells (human neutrophils).

[0108] 1) Cell culture environment and solutions used: All cells were cultured in a sterile cell culture incubator at 37°C and 5% CO2. E-SW480, M-SW480, A549, MCF-7, and THP-1 cells were cultured in 1640 medium (containing 10% fetal bovine serum), and Hela cells were cultured in DMEM medium (containing 10% fetal bovine serum).

[0109] 2) Cell counting: After cell passaging is completed, use a cell counter to count the cells. Before the experiment, use PBS solution to dilute the cell solution to the required concentration of the experiment.

[0110] 3) Cell fixation and staining;

[0111] Cell fixation and permeabilization: After collecting cells according to the above cell passage steps, add an appropriate amount of 4% paraformaldehyde solution, gently blow the cell solution to make it dispersed evenly, and let it stand at room temperature for 10 minutes. After the cells are fixed, resuspend and wash once with physiological saline, then add PBS solution containing 0.1% Triton X-100, gently blow the cells to make them dispersed evenly, and let it stand at room temperature for 10 minutes. After cell permeabilization, add PBS solution containing 2% BSA to block, let it stand at room temperature for 30 minutes, and finally resuspend in PBS solution.

[0112] Cell DAPI staining: After the cells are fixed and permeabilized, add DAPI staining solution under light-proof conditions, blow gently, blow evenly, place at room temperature in the dark for 5 minutes, centrifuge at the specified speed to discard the supernatant, then add an appropriate amount of physiological saline and blow slowly to disperse the cell pellet evenly, centrifuge again at the specified speed, and wash away the excess DAPI staining solution. Finally, add PBS solution and blow gently to disperse the cells evenly, and observe the sample under an inverted fluorescence microscope. Cell Anti-CD45 antibody staining: Under light-proof conditions, add PBS solution containing Anti-CD45 antibody (30μg / mL) to the fixed and permeabilized cell solution, blow gently, blow evenly, and place in a 4℃ refrigerator in the dark overnight. After incubation, centrifuge at the specified speed, then add PBS solution to wash away excess antibodies, and finally add PBS solution and blow gently to disperse the cells evenly, and observe the sample under an inverted fluorescence microscope. Cell Anti-CK19 antibody staining: Add PBS solution containing Anti-CK19 antibody (30μg / mL) to the fixed permeabilized cell solution under light-proof conditions, gently blow, and place in a 4℃ refrigerator in the dark overnight for incubation. After incubation, centrifuge at the specified speed, then add PBS solution to wash away excess antibodies, and finally add PBS solution and gently blow to disperse the cells evenly, and observe the sample under an inverted fluorescence microscope.

[0113] (IV) E-SW480 cell mesenchymal induction experiment;

[0114] Starvation experiment: After cell passage, culture in a sterile cell culture incubator at 37°C and 5% CO2 for 24 hours. After the E-SW480 cells adhere to the wall, discard the complete medium in the cell culture flask, then add 5.0mL of physiological saline, gently rinse the surface of the adherent cells, and then add fresh 1640 incomplete medium to 4mL. Induction experiment: Add 5.0mL of 1640 complete medium containing TGF-β (10ng / mL) to the E-SW480 that has been starved for 24 hours, and finally place it in a sterile cell culture incubator at 37°C and 5% CO2 for continued culture. After 3 consecutive days of culture, interstitial M-SW480 cells were obtained.

[0115] The cells were fixed, permeabilized, and stained with DAPI. Immunofluorescence was used to detect the expression levels of EpCAM and Vimentin on the surface of SW480 cells before and after induction to investigate whether SW480 cells had become mesenchymal. Figure 6 and Figure 7 As shown in the figure, the expression level of EpCAM on the surface of SW480 cells induced by TGF-β was significantly lower than that of uninduced SW480 cells, while the expression level of Vimentin on the surface of SW480 cells induced by TGF-β was significantly higher than that of uninduced SW480 cells, indicating that E-SW480 cells have been successfully induced into M-SW480 cells. Therefore, the induced SW480 cells can be used as M-SW480 cells for subsequent experiments.

[0116] (V) Verification of CTCs capture by Gel-GO / Apt hydrogel;

[0117] like Figure 8 As shown in the figure, the surface morphology of the Gel-GO / Apt hydrogel captured with E-SW480 and M-SW480 cells was observed using SEM. It can be clearly observed that both E-SW480 cells and M-SW480 cells are captured on the surface of the hydrogel membrane. The E-SW480 cells and M-SW480 cells captured on the surface of the Gel-GO / Apt hydrogel have extended some pseudopodia to fix themselves, which may be due to the micron-scale structure of the Gel-GO surface that increases the interaction between cells and hydrogels. Aptamer-modified Gel-GO hydrogels can be used to specifically capture CTCs.

[0118] (VI) Comparative verification of the CTCs capture performance of different materials;

[0119] The materials in the capture area of ​​the chip were replaced with gelatin (Gel), gelatin / Apt (Gel / Apt), gelatin-graphene oxide hydrogel (Gel-GO), and gelatin-graphene oxide / Apt hydrogel (Gel-GO / Apt), respectively. Then, the E-SW480 cells were passaged, collected, and counted. According to the counting results, the E-SW480 cell solution was diluted with PBS solution to a cell solution of 1000 cells / mL, and 1 mL of 1000 cells / mL cell solution was injected into the chip using a syringe pump. After the cell solution was injected, PBS solution (pH = 7.4) was added to wash 3 times. The captured cells treated according to the fixation, permeabilization, and DAPI staining steps were observed using an inverted fluorescence microscope, and the supernatant solution was aspirated and counted using a flow cytometer to compare the differences in the capture efficiency of CTCs by different materials.

[0120] Results: The results are as follows Fig. 9 As shown in the figure, compared with pure gelatin, whether modified with aptamers or not, the capture efficiency of E-SW480 cells by Gel-GO / Apt hydrogel is significantly higher than that of pure gelatin and the other three materials, and under a fluorescence microscope, the number of cells after DAPI nuclear staining is also the largest on Gel-GO / Apt hydrogel. This result fully demonstrates that CTCs tend to bind to Gel-GO hydrogels with rough tissue structures by enhancing structural interactions.

[0121] (VII) Experiment on optimization of conditions for capturing CTCs on chip: optimization of graphene oxide content in Gel-GO hydrogel;

[0122] E-SW480 cells were passaged and collected, and the E-SW480 cell solution was diluted with PBS solution to a cell solution of 500 cells / mL. Gel-GO hydrogels with graphene oxide contents of 0, 0.2, 0.4, 0.6, 0.8, and 1.0 mg / mL were used to modify the capture area of ​​the chip, and then 1 mL of the above cell solution was injected into the area to fully react with the hydrogel for a certain period of time. Then the filtrate was taken out from the small hole reserved above the capture area of ​​the chip, and the remaining CTCs cells in the filtrate were counted using a flow cytometer to compare the capture efficiency of E-SW480 cells by Gel-GO / Apt hydrogels with different graphene oxide contents (capture efficiency = (total number of cells-number of cells in the filtrate) / total number of cells × 100%). The content corresponding to the highest capture efficiency is the optimal content of graphene oxide in the hydrogel, and is used in subsequent experiments.

[0123] Results: The capture efficiency of pure gelatin without graphene oxide and only modified with aptamers was the lowest, only 61.6%. When the content of graphene oxide increased to 0.4 mg / mL, the capture efficiency of E-SW480 reached the highest, 91.51%. With the increase of graphene oxide content, the capture efficiency gradually decreased. This may be because after the content of graphene oxide in gelatin increased, the amount of graphene oxide on the surface of the hydrogel increased, which indirectly affected the number of amino aptamers binding to gelatin. Therefore, in subsequent experiments, Gel-GO hydrogel with a graphene oxide content of 0.4 mg / mL was used for experiments. After determining the optimal concentration, Gel-GO hydrogel modified with vimentin aptamer was used to capture M-SW480. The capture efficiency of M-SW480 by Gel-GO hydrogel modified with vimentin aptamer was also very high, basically equivalent to the capture efficiency of E-SW480.

[0124] (VIII) Capture efficiency of CTCs in two media: PBS and mixed cells;

[0125] E-SW480 and M-SW480 cells were passaged and collected, and the cell solutions were counted. According to the counting results, PBS solution was used to prepare 5, 10, 20, 50, 100, 200, and 500 cells / mL of E-SW480 and M-SW480 cells. 1 mL of the above PBS solution of E-SW480 and M-SW480 cells was injected into the capture chip and fully reacted with the Gel-GO / Apt hydrogel on the chip substrate. The filtrate was taken out from the small hole reserved above the capture area, and the CTCs in the filtrate were counted using a flow cytometer to calculate the capture efficiency of Gel-GO / Apt hydrogel for each concentration of E-SW480 and M-SW480 cells in the PBS medium. 1×10 6 The cell solution of THP-1 was added, and the above operation was repeated to calculate the capture efficiency of the capture chip for different numbers of CTCs in mixed cells. The cells were stained with DAPI, Anti-CD45, and Anti-CK19 antibodies, and the cells captured by Gel-GO / Apt hydrogel were observed and counted using an inverted fluorescence microscope, and then the capture efficiency of Gel-GO / Apt hydrogel for each number of E-SW480 and M-SW480 cells was calculated.

[0126] Results: Fig.10As shown in the figure, with the increase of the number of E-SW480 and M-SW480 cells, Gel-GO / Apt hydrogel can show excellent capture ability, and the average capture efficiency can reach 90%. Even when the number of cells is equal to 10 / mL, the capture efficiency of the hydrogel for the two cells can still reach 90% and 83.3%. Although the capture efficiency of Gel-GO / Apt hydrogel for E-SW480 cells in the mixed cell solution containing THP-1 is slightly lower than that in the PBS medium, the capture efficiency can still reach more than 90%. Its linear regression equations in the mixed cell medium under the background of PBS and THP-1 are Y=0.940X-0.335(R 2 =0.998) and Y = 0.928X-0.330 (R 2 =0.999), M-SW480: Y=0.906X-0.560(R 2 =0.998) and Y = 0.900X-0.083 (R 2 =0.999)( Fig.10 C and D in Figure 3). The linear regression curves in different media are basically overlapped, indicating that there is no significant difference in the ability of Gel-GO / Apt hydrogel to capture CTCs in the two media.

[0127] (IX) Feasibility of mPtNPs / Apt probe in detecting epithelial and stromal CTCs

[0128] E-SW480 cells were passaged and collected, the cell solution was counted, and the E-SW480 cell solution was diluted with PBS solution to 500 cells / mL. First, according to the steps of chip capture cells, Gel-GO / Apt hydrogel was used to capture 1mL of 500 / mL E-SW480 cell solution and blank PBS solution using a microfluidic chip. After rinsing the chip with PBS, 100μL of 20μg / mL mPtNPs / Apt was continued to be dripped into the capture area. After incubation at room temperature for 30 minutes, the excess mPtNPs / Apt was washed off, and 200μL of a mixed solution of 0.5mM TMB and 50mM H2O2 was added. After incubation for 10 minutes, TMB reaction termination solution without sulfuric acid was added, and the filtrate was taken out from the small hole reserved above the capture area. Finally, the absorbance of the solution was detected using a UV spectrophotometer, and the results were compared with those of the blank group. Then, the E-SW480 cell solution was replaced with an M-SW480 cell solution or a mixed cell solution of M-SW480 and THP1, and the above process was repeated.

[0129] Results: After completing the capture of E-SW480 and M-SW480 cells by the Gel-GO / Apt hydrogel-based capture chip, the mesoporous platinum nanoparticles / EpCAM aptamer (mPtNPs / Apt EpCAM ) and mesoporous platinum nanoparticles / Vimentin aptamers (mPtNPs / Apt vimentin ) two detection probes are added to the two capture areas of the chip respectively. According to the detection principle, after the detection probes are added to the two areas for incubation, the CTCs captured on the hydrogel will recognize the two aptamers on the detection probes, and then bind to the detection probes to form a sandwich structure. At this time, a mixed solution of 0.5mM TMB and 50mM H2O2 is added to the chip. In the presence of H2O2, the colorless TMB is catalyzed by the mPtNPs specifically bound to the surface of CTCs to a blue oxidation state, producing characteristic absorption at a certain wavelength. The more CTCs there are, the more mPtNPs / Apts are bound, and the higher the absorbance value generated by catalyzing TMB. Therefore, the counting analysis of CTCs can be realized according to the size of the absorbance value at a specific wavelength. The same concentration of TMB and (TMB+H2O2) are set as the control group, and CTCs+TMB+H2O2 is used as the experimental group. Fig.11 The absorption spectrum results show that the absorbance values ​​of TMB detected in the two control groups at around 650nm are relatively low. After adding TMB and H2O2 solutions to CTCs, the absorption peak detected at 650nm is 0.482, which is 16 times and 4.4 times the response values ​​of the TMB control group and the (TMB+H2O2) control group. This result shows that it is fully feasible to use the mPtNPs / Apt probe to detect captured CTCs. Next, after the Gel-GO / Apt hydrogel captured the E-SW480 cells, mPtNPs / Apt was added to incubate with the cells. After the incubation, the samples were fixed, dehydrated, and freeze-dried. The surface morphology was observed and photographed using a SEM scanning electron microscope to further and more intuitively verify the bioconjugation of mPtNPs / Apt and E-SW480 cells. Fig.12 As shown, in the high-resolution SEM image, not only the captured E-SW480 cells can be seen, but also a large number of mPtNPs bound to the surface of E-SW480 cells can be seen, further proving the binding of mPtNPs / Apt to E-SW480 cells.

[0130] (X) Specificity of mPtNPs / Apt in detecting epithelial and stromal CTCs;

[0131] E-SW480 cells were passaged and collected, and the cell solution was counted. According to the counting results, the E-SW480 cell solution was diluted with PBS solution to 500 cells / mL. First, according to the steps of chip capture cells, 1mL of 500 / mL E-SW480 cell solution was captured by Gel-GO / Apt hydrogel in the microfluidic chip. After rinsing the chip with PBS, 100μL of 20μg / mL mPtNPs / Apt solution was added to the epithelial and interstitial capture areas respectively. After incubation at room temperature for 30 minutes, the excess mPtNPs / Apt was washed off, and 200μL of a mixed solution of 0.5mM TMB and 50mM H2O2 was added. After incubation for 10 minutes, the TMB reaction termination solution without sulfuric acid was added, and the filtrate was taken out from the small hole reserved above the capture area. Finally, the absorbance of the solution in the epithelial and interstitial capture areas was detected using a UV spectrophotometer. Then, the E-SW480 cell solution was replaced with A549, MCF-7, M-SW480, Hela, and THP-1 cell solutions, and the above process was repeated.

[0132] Results: EpCAM-positive, Vimentin-negative CTCs (E-A549, A549, MCF-7), EpCAM-negative, Vimentin-positive CTCs (M-A549, Hela) and normal human cells (THP-1) were captured, and then the absorbance was measured in the epithelial CTCs and mesenchymal CTCs capture areas. The differences in absorbance data between the groups of cells were compared to explore whether the probe is specific for the detection of CTCs. The results are shown in Fig.13 As shown, for EpCAM-positive and Vimentin-negative CTCs such as E-A549, A549, and MCF-7, the absorbance value detected in the epithelial detection area is relatively high, much higher than the signal in the interstitial detection area. Similarly, for M-A549 and Hela cells that are EpCAM-negative and Vimentin-positive, high absorption values ​​were detected in the interstitial detection area modified with the Vimentin aptamer. However, for normal human cells THP-1, which are negative for both EpCAM and Vimentin expression, when added to the chip, no significant absorption signal was generated in either the epithelial CTCs detection area or the interstitial CTCs detection area. This is mainly due to the lack of specific antigens on THP-1 cells that can bind to the mPtNPs / Apt probe, resulting in the mPtNPs / Apt probe being unable to be fixed in the chip. The above results fully demonstrate that the cascade chip designed by the present invention and the mPtNPs / Apt probe are highly specific for the detection of heterogeneous CTCs.

[0133] (XI) Optimization of CTCs detection conditions;

[0134] 1) Optimization of the concentration of mPtNPs / Apt probe: E-SW480 cells were passaged and collected, the cell solution was counted, and the E-SW480 cell solution was diluted with PBS solution to a cell solution of 500 cells / mL. First, according to the steps of chip capture cells, 1mL of 500 / mL E-SW480 cell solution was captured using the Gel-GO / Apt hydrogel in the microfluidic chip. After rinsing the chip with PBS, 100μL of 0, 5, 10, 20, 50, μg / mL mPtNPs / Apt solution was dripped into the epithelial capture area, and then the absorbance of each solution was detected using a UV spectrophotometer, and the absorbance of probe solutions of different concentrations was compared. The probe concentration with the maximum absorbance was the optimal concentration, and subsequent experiments were carried out at this concentration.

[0135] 2) Optimization of the incubation time between mPtNPs / Apt probe and CTCs: M-SW480 cells were passaged and collected, the cell solution was counted, and the E-SW480 cell solution was diluted with PBS solution to a 500 cell / mL cell solution. First, according to the steps of chip capture cells, 1mL of 500 / mL E-SW480 cell solution was captured using the Gel-GO / Apt hydrogel in the microfluidic chip. After rinsing the chip with PBS, 100μL of 20μg / ml mPtNPs / Apt solution was added to the capture area respectively. After incubation at room temperature for 15, 20, 25, 30, and 40 minutes, the absorbance of each solution was detected. The incubation time corresponding to the highest absorbance was the optimal incubation time, and this incubation time was used in subsequent experiments.

[0136] Results: The absorbance value at 450nm was detected by ultraviolet spectrophotometer. According to the response principle of the probe to E-SW480, after incubation with E-SW480 cells, the greater the absorbance of the TMB after color development, the higher the detection sensitivity under this condition. When the probe concentration was 20μg / mL, the absorbance remained basically unchanged. Therefore, 20μg / mL was used as the optimal concentration of the probe. Then, the incubation time of the mPtNPs / Apt probe with M-SW480 was optimized. When the probe was incubated with M-SW480 for 30min, the absorbance of TMB detected at this time was the highest, indicating that the EpCAM site on the surface of M-SW480 cells has been basically covered by the probe. Therefore, 30min was used as the optimal time for incubation of the mPtNPs / Apt probe with CTCs.

[0137] (XII) Investigation of the linear relationship between the number of CTCs and the absorbance intensity of TMB;

[0138] E-SW480 and M-SW480 cells were passaged and collected, and the cell solutions were counted. The E-SW480 and M-SW480 cell solutions were diluted with PBS solution to 500 cells / mL. They were diluted to 5, 10, 20, 50, 100, 200, and 500 cells / mL. First, according to the steps of chip capture cells, the Gel-GO / Apt hydrogel in the microfluidic chip was used to capture the above-mentioned different numbers of E-SW480 cell solutions, detect the absorbance of each solution, and draw a linear relationship curve between the number of CTCs and the absorbance value. Then replace the above PBS with a solution containing 1×10 6 Repeat the above experimental steps for the mixed cell solution of 10 leukocytes.

[0139] Results: The results are as follows Fig.14 and Fig.15 As shown: Fig.14 It can be seen that with the increase in the number of E-SW480 and M-SW480 cells, the absorbance of TMB at 450nm gradually increased ( Fig.14 The number of E-SW480 and M-SW480 cells were both within the range of 5 to 500 / mL, showing a good linear correlation with the absorbance value. The linear regression equations of the two were Y = 0.381lgX-0.070 (R 2 =0.994), Y=0.334lgX-0.024(R 2 =0.993)( Fig.14 C in the figure). The above results show that the mPtNPs / Apt probe can sensitively detect heterogeneous CTCs captured by Gel-GO / Apt hydrogel in the chip. Fig.15 As shown, in the presence of 1×10 6 In the mixed cell medium of THP-1 cells, as the number of E-SW480 and M-SW480 cells increased, the absorption peak intensity of TMB also increased, and there was also a good linear relationship between the absorbance value and the number of cells, which was highly similar to the research results in PBS medium. In the mixed cell medium, the linear regression equations between the number of E-SW480 and M-SW480 cells and the absorption peak intensity of TMB were Y=0.403lgX-0.063(R 2 =0.994), Y=0.345lgX-0.014(R 2 =0.994), which was not significantly different from the linear relationship in PBS medium. The above results show that the number of CTCs and TMB absorbance have a good linear relationship in two different media, which can be attributed to the filtering of white blood cells by the microfluidic chip, which greatly reduces the complex background. At the same time, it also further proves the feasibility of this method for heterogeneous CTCs detection.

[0140] Example 3: Testing of whole blood samples collected from 20 patients with colon cancer and 10 healthy volunteers in a hospital

[0141] Whole blood samples from 20 patients with colon cancer and 10 healthy volunteers were collected in a hospital and preserved in EDTA-K2 anticoagulant tubes. The microfluidic chip prepared by the present invention was used for cell capture. Then, the mPtNPs / Apt probe was added, and the absorbance of TMB was measured in the presence of H2O2. The number of CTCs in 1.0 mL of blood sample was calculated based on the linear regression equation obtained in the mixed cells.

[0142] 1) Epithelial CTCs capture detection area, the relationship between the absorbance value after reaction and the number of epithelial CTCs cells is as follows:

[0143] Y=0.403lgX-0.063,R 2 =0.994, where X represents absorbance and Y represents the number of cells.

[0144] 2) In the interstitial CTCs capture detection area, the relationship between the absorbance value after the reaction and the number of interstitial CTCs cells is as follows:

[0145] Y=0.345lgX-0.014,R 2 =0.994, where X represents absorbance and Y represents the number of cells.

[0146] result Fig.16 and Fig.17 As shown: Fig.16 The clinical stage of cancer in patients No. 1-3 is stage I, the clinical stage of cancer in patients No. 4-9 is stage II, the clinical stage of cancer in patients No. 9-14 is stage II, the clinical stage of cancer in patients No. 15-20 is stage IV, and No. 21-30 are healthy volunteers. No CTCs were detected in healthy volunteers. Epithelial CTCs were detected in all patients, and no stromal CTCs were detected in patients No. 1 to 8. The total number of CTCs was between 0 and 26 / mL, the number of cells with high expression of EpCAM was between 5 and 10 / mL, and the number of cells with high expression of Vimentin was between 0 and 19. Fig.17 is the relationship between the total number of CTCs and the proportion of epithelial and stromal CTCs in the total CTCs and the clinical stage. Fig.17 As can be seen in Figure A, the total number of CTCs increases with the progression of cancer stage. Fig.17B in the figure shows that CTCs in the blood samples of patients in stages I and II mainly express EpCAM, while CTCs in the blood samples of patients in stages III and IV mainly express Vimentin, and as the clinical stage progresses, the proportion of cells expressing Vimentin in the total CTCs gradually increases. It can be seen that CTCs can be quantified based on the epithelial marker EpCAM and the mesenchymal marker Vimentin of tumor cells, and cells can be accurately quantified based on the protein markers highly expressed on their surface. The microfluidic chip and mPtNPs / Apt probe of the present invention can complete the real-time detection of heterogeneous CTCs in whole blood samples, and explore the correlation between the number of CTCs and the proportion of cells expressed by epithelial and mesenchymal cells in the total CTCs and clinical stage, showing the potential of this method in clinical application.

[0147] The Chinese names corresponding to the abbreviations involved in the embodiments of the present invention

[0148]

[0149] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention.

Claims

1. Application of a microfluidic chip in the capture and detection of heterogeneous CTCs in colon cancer, characterized in that: The steps include: Step 1: preparing a microfluidic chip; The microfluidic chip includes a spiral separation chip and an immune capture detection chip arranged in cascade; The spiral separation chip comprises a single spiral microfluidic channel, wherein the first end of the single spiral microfluidic channel is located inside the single spiral microfluidic channel, and the second end of the single spiral microfluidic channel is located outside the single spiral microfluidic channel, and the first end of the single spiral microfluidic channel is provided with two inlets, namely a sheath flow inlet and a sample inlet, and the sheath flow inlet is located inside, and the sample inlet is located outside; the second end of the single spiral microfluidic channel is provided with two outlets, namely a target outlet and a waste liquid outlet, and the target outlet is located inside, and the waste liquid outlet is located outside; The immune capture detection chip is provided with an import channel, a first groove, a connecting channel, a second groove, and an export channel which are connected in sequence; the first groove is an epithelial CTCs capture detection area, and the second groove is an interstitial CTCs capture detection area; the first groove is provided with a Gel-GO hydrogel modified with an NH2-EpCAM aptamer, and the second groove is provided with a Gel-GO hydrogel modified with an NH2-Vimentin aptamer; The target outlet of the spiral separation chip is connected to the inlet channel of the immune capture detection chip; Step 2: Isolation of heterogeneous CTCs; The blood sample to be tested first enters the spiral separation chip, and then is separated to obtain heterogeneous CTCs; the heterogeneous CTCs include epithelial CTCs and mesenchymal CTCs; Step 3: Capture of heterogeneous CTCs; The heterogeneous CTCs flowing out of the target outlet of the spiral separation chip enter the immune capture detection chip through the inlet channel of the immune capture detection chip, and the epithelial CTCs in the blood sample to be detected are captured by the first groove, and the interstitial CTCs are captured by the second groove; Step 4: Detection of heterogeneous CTCs; 1) Drop the SH2-EpCAM aptamer-modified mPtNPs solution into the first groove, i.e., mPtNPs / Apt EpCAM solution, and then add a mixed solution of TMB and H2O2 after incubation; 2) Add the solution of mPtNPs modified with SH-Vimentin aptamer into the second groove, i.e., mPtNPs / Apt vimentin solution, and then add a mixed solution of TMB and H2O2 after incubation; 3) The mPtNPs were used to catalyze the color development reaction of TMB, and the relationship between the absorbance value and the number of cells after the reaction between the epithelial CTCs capture detection area and the mesenchymal CTCs capture detection area was detected, and the number of epithelial CTCs and mesenchymal CTCs was calculated.

2. The use according to claim 1, characterized in that: In step one: 1) The channel width of the single spiral microfluidic channel is 350 μm, the depth is 150 μm, and the curvature diameter is 1 cm; 2) In the immune capture detection chip, the width and depth of the inlet channel, the connecting channel, and the outlet channel are all 1 mm, the depth of the first groove and the second groove is 6 mm, and the bottom area is 0.95 cm 2 .

3. The use according to claim 1, characterized in that: In step 1, the preparation method of the Gel-GO hydrogel modified with NH2-EpCAM aptamer and the Gel-GO hydrogel modified with NH2-Vimentin aptamer on the immune capture detection chip is as follows: Step 1.1), preparing gelatin-graphene oxide hydrogel; 1 mL of 2 mg / mL graphene oxide suspension was taken into a centrifuge tube and dispersed evenly by ultrasound; then 15 wt% gelatin solution was added to 5 mL and stirred at 37°C for 30 min to obtain gelatin-graphene oxide hydrogel, i.e., Gel-GO hydrogel. The concentration of graphene oxide in the Gel-GO hydrogel was 0.4 mg / mL; Step 1.2) Adaptogenized Gel-GO hydrogel; The prepared Gel-GO hydrogel was added into the first groove and the second groove, and placed in a 4°C refrigerator for 30 minutes to gradually change the Gel-GO hydrogel from a solution state to a solid state; then a mixed solution of 4 mg / mL EDC and 6 mg / mL NHS was added, and the mixture was reacted at room temperature for 2 hours to activate the carboxyl group. After the activation was completed, the mixture was rinsed with a PBS buffer solution; Add 200 μL of 1.0 μM NH2-EpCAM aptamer to each of the first grooves, place in a 4°C refrigerator, and incubate for 12 h. After the incubation, rinse with PBS buffer solution to obtain NH2-EpCAM aptamer-modified Gel-GO hydrogel; Add 200 μL of 1.0 μM NH2-Vimentin aptamer into the second groove, place it in a 4°C refrigerator, and incubate it at low temperature for 12 hours; after incubation, rinse it with PBS buffer solution to obtain NH2-Vimentin aptamer-modified Gel-GO hydrogel.

4. The use according to claim 1, characterized in that: In step 2, the separation flow rate of the blood sample to be tested entering the spiral separation chip is 350 μL / min for the sample flow rate and 700 μL / min for the sheath flow rate.

5. The use according to claim 1, characterized in that: In step 4, mPtNPs / Apt EpCAM Solution and mPtNPs / Apt vimentin The solution was prepared as follows: 1) Mix 100.0 μL of 15.0 μM SH-EpCAM aptamer and SH-Vimentin aptamer with 2.5 μL of 1.0 M TCEP solution respectively and incubate at room temperature for 30 min to activate the thiol groups; 2) After activation, 1.0 mL and 5 mg / mL of mPtNPs were vortexed and mixed with the activated SH-EpCAM aptamer and SH2-Vimentin aptamer respectively to make the final concentration of the aptamer 1.0 μM; 3) Finally, the mixed solution was reacted in a vertical suspension instrument at room temperature for 12 h to obtain two types of mPtNPs modified with SH-EpCAM aptamer and SH-Vimentin aptamer, which were respectively denoted as mPtNPs / Apt EpCAM and mPtNPs / Apt vimentin ; 4) After the reaction, centrifuge at 12,000 rpm for 15 min to remove the unbound aptamers in the supernatant, and finally redisperse in PBS solution to obtain mPtNPs / Apt EpCAM Solution and mPtNPs / Apt vimentin Solution, store at 4°C.

6. The use according to claim 5, characterized in that: Step 4 is as follows: 1) Add mPtNPs / Apt into the first groove EpCAM The volume of the solution was 100 μL, mPtNPs / Apt EpCAM The concentration of mPtNPs / Apt was 20 μg / mL. After incubation at room temperature for 30 min, the excess mPtNPs / Apt EpCAM The solution was washed off, and 200 μL of a mixed solution of 0.5 mM TMB and 50 mM H2O2 was added. After incubation for 10 min, TMB reaction stop solution without sulfuric acid was added; 2) Add mPtNPs / Apt into the second groove vimentin 100 μL of solution, mPtNPs / Apt vimentin The concentration was 20 μg / mL. After incubation at room temperature for 30 min, the excess mPtNPs / Apt was washed off and 200 μL of a mixed solution of 0.5 mM TMB and 50 mM H2O2 was added. After incubation for 10 min, TMB reaction termination solution without sulfuric acid was added. 3) Epithelial CTCs capture detection area, the relationship between the absorbance value after reaction and the number of epithelial CTCs cells is as follows: Y=0.403lgX-0.063,R 2 =0.994; Among them, X represents absorbance and Y represents the number of cells; 4) In the interstitial CTCs capture detection area, the relationship between the absorbance value after the reaction and the number of interstitial CTCs cells is as follows: Y=0.345lgX-0.014,R 2 =0.994; Among them, X represents absorbance and Y represents the number of cells.